Canakinumab

(Ilaris®)

Ilaris®

Drug updated on 4/17/2024

Dosage FormInjection (subcutaneous; 150 mg/mL)
Drug ClassInterleukin-1β blockers
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of periodic fever syndromes: Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older, including: Familial Cold Auto-inflammatory Syndorme (FCAS) and Muckle-Wells Syndrome (MWS).
  • Indicated for the treatment of periodic fever syndromes: Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients.
  • Indicated for the treatment of periodic fever syndromes: Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients.
  • Indicated for the treatment of periodic fever syndromes: Familial Mediterranean Fever (FMF) in adult and pediatric patients.
  • Indicated for the treatment of Active Still’s disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older.
  • Indicated for the treatment of Gout flares in adults in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated, with no liability accepted for reliance on it. Learn more.

  • Canakinumab (Ilaris) is a human monoclonal antibody targeting interleukin-1 beta, used for treating various auto-inflammatory syndromes such as Cryopyrin-Associated Periodic Syndromes, Tumor Necrosis Factor Receptor Associated Periodic Syndrome, Hyperimmunoglobulin D Syndrome/Mevalonate Kinase Deficiency, Familial Mediterranean Fever, Active Still’s Disease, and Gout flares.
  • Fifteen systematic reviews/meta-analyses were analyzed to gather information about the drug's effectiveness and safety profile.
  • In comparison with triamcinolone in Gout flare treatment scenarios where standard therapies are unsuitable, canakinumab significantly improved patient outcomes by reducing serum hsCRP and Amyloid A levels, along with improving patient and physician global assessments. It also outperformed anakinra and rilonacept in reducing Visual Analogue Scale score frequency of gout flares.
  • For Familial Mediterranean Fever cases resistant or intolerant to colchicine; both adult and pediatric populations displayed high efficacy rates under anti-interleukin therapy using canakinumab. Studies indicated that 60% of adult patients achieved complete remission, while this figure was higher at 81% for pediatric patients.
  • Canakinumab demonstrated significant efficacy in producing complete remission of systemic manifestations associated with Adult-Onset Still’s Disease and had the highest probability of being the best treatment option for Systemic Juvenile Idiopathic Arthritis without posing any significant risk related to serious adverse events.
  • Pregnancy-related considerations indicate that the use of canakinumab did not increase the rate of adverse perinatal outcomes, suggesting its safe usage during the pregnancy period when dealing with inflammatory diseases.
  • In terms of attack prevention and inflammation reduction, especially in colchicine-resistant Familial Mediterranean Fever cases, evidence suggested favorable outcomes with canakinumab, which resulted in a significant reduction in participants experiencing attacks and a decrease in CRP levels.
  • The comparative analysis with other treatments such as corticosteroids, NSAIDs, and IL-1β inhibitors like anakinra and rilonacept showed that canakinumab often had superior efficacy in symptom control, along with a manageable safety profile.

Product Monograph / Prescribing Information

Document TitleYearSource
Ilaris (canakinumab) Prescribing Information. 2023Novartis Pharmaceuticals Corporation East Hanover, NJ

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Interleukin-1β inhibitors for the management of acute gout flares: a systematic literature review.2023Arthritis Research & Therapy
Efficacy and safety of anti-ınterleukin-1 treatment in familial Mediterranean fever patients: a systematic review and meta-analysis.2023Rheumatology
The effect of canakinumab on clinical outcomes in patients with COVID-19: a meta-analysis.2022Journal of Infection
Systematic review of safety and efficacy of IL-1-targeted biologics in treating immune-mediated disorders.2022Frontiers in Immunology
Interventions for reducing inflammation in familial Mediterranean fever. 2022The Cochrane Database of Systematic Reviews
Efficacy and safety of canakinumab in the treatment of adult-onset Still's disease: a systematic review.2021Seminars in Arthritis and Rheumatism
A systematic review of the safety of blocking the IL-1 system in human pregnancy.2021Journal of Clinical Medicine
Effect of canakinumab on clinical and biochemical parameters in acute gouty arthritis: A meta-analysis.2021Inflammopharmacology
Update on the therapy of adult-onset Still's disease with a focus on IL-1-inhibition: a systematic review. 2021Therapeutic Advances in Musculoskeletal Disease
Comparison of the efficacy and safety of biological agents in patients with systemic juvenile idiopathic arthritis: a Bayesian network meta-analysis of randomized controlled trials.2021International Journal of Clinical Pharmacology and Therapeutics
Efficacy and safety of pharmacologic interventions in patients experiencing a gout flare: a systematic review and network meta-analysis.2021Arthritis Care & Research
Efficacy and safety of canakinumab treatment in Schnitzler syndrome: a systematic literature review.2020Seminars in Arthritis and Rheumatism
The efficacy, safety and tolerability of canakinumab in the treatment of familial mediterranean fever: a systematic review of the literature.2020Journal of Inflammation Research
Systematic literature review of efficacy/effectiveness and safety of current therapies for the treatment of cryopyrin-associated periodic syndrome, hyperimmunoglobulin D syndrome and tumour necrosis factor receptor-associated periodic syndrome.2020Rheumatic & Musculoskeletal Diseases Open
A systematic literature review of efficacy, effectiveness and safety of biologic therapies for treatment of familial Mediterranean fever.2020Rheumatology
The right place of interleukin-1 inhibitors in the treatment of Bechet’s syndrome: a systematic review.2019Rheumatology International

Clinical Practice Guidelines